Navigation Links
Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Date:12/3/2010

MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available at the following URL:  

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3331020

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate).On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides(>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information, including a summary of MARINE trial top-line results, please visit www.amarincorp.com.Investor Contact Information: John F. Thero President In U.S.: +1 (860) 572-4979 investor.relations@amarincorp.
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
2. Amarin to Present at UBS Life Sciences Conference
3. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
4. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
5. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
6. VIVUS to Present at Two Upcoming Investor Conferences
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
9. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
10. Masimo to Present at Piper Jaffray 22nd Annual Healthcare Conference
11. Beckman Coulter to Present at the Piper Jaffray 22nd Annual Unplugged Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... HealthDay Reporter , WEDNESDAY, April 11 (HealthDay News) -- ... of the postoperative experience of four children who all carried ... to three of the patients, while a similar case came ... genetic cases, the common painkiller codeine can be lethal. The ...
... published article in the journal Nursing for Women,s Health ... her childbearing. The author asserts that contraception is a means ... care providers to ensure they are healthy prior to conceiving ... According to the Centers for Disease Control and Prevention ...
... Regular walking can help reduce fatigue in some pancreatic cancer ... white men and women aged 66 or 67 who underwent ... before they were discharged from the hospital. One group ... a walking or exercise routine. The other group was told ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, April ... birth controls pills containing drospirenone -- a man-made version of ... risk of blood clots and will require new labels. ... will inform users that the pills -- which include products ...
... April 11, 2012. Anna M. Barrett, MD will represent ... American Academy of Neurology Conference at the Ernest N. ... April 28. Four abstracts will be presented ... of spatial neglect after right-brain stroke. Spatial neglect is ...
... that women are less likely than men to get at ... odds of developing metabolic syndrome a risky and increasingly ... name for a group of risk factors including high ... part of the body which occur together and increase ...
Cached Medicine News:Health News:Codeine After Surgery Could Endanger Certain Kids: Study 2Health News:Codeine After Surgery Could Endanger Certain Kids: Study 3Health News:Codeine After Surgery Could Endanger Certain Kids: Study 4Health News:Timing pregnancy an important health concern for women 2Health News:Short Walks May Ease Fatigue in Pancreatic Cancer Patients 2Health News:Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA 2Health News:NJ stroke researchers report advances in spatial neglect research at AAN Conference 2Health News:Study: Women not getting enough exercise; at risk of developing metabolic syndrome 2
Inquire...
... performance, the SZX7 is designed for ease ... task, from routine preparations to advanced research. ... zoom ratios in its class as well ... accurate reproduction of the original specimen in ...
The Stereomicroscope Stemi 2000 meets your demands in two respects. On the one hand it offers the low-price advantage common with Greenough-type instruments, on the other hand it features superior pe...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Medicine Products: